SJS Investment Consulting’s CRISPR Therapeutics CRSP Stock Holding History

SJS Investment Consulting’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.98K	Buy	128 +94	+276%	+$4.96K	﹤0.01%	1242
2026 Q1	$1.62K	Hold	34	–	–	﹤0.01%	1330
2025 Q4	$1.78K	Hold	34	–	–	﹤0.01%	1165
2025 Q3	$2.2K	Hold	34	–	–	﹤0.01%	805
2025 Q2	$1.65K	Hold	34	–	–	﹤0.01%	633
2025 Q1	$1.16K	Hold	34	–	–	﹤0.01%	953
2024 Q4	$1.34K	Sell	34 -30	-47%	-$1.42K	﹤0.01%	898
2024 Q3	$3.01K	Sell	64 -370	-85%	-$18.8K	﹤0.01%	624
2024 Q2	$23.4K	Buy	434 +20	+5%	+$1.16K	﹤0.01%	251
2024 Q1	$28.2K	Hold	414	–	–	0.01%	241
2023 Q4	$25.9K	Buy	414 +10	+2%	+$553	0.01%	218
2023 Q3	$18.3K	Buy	404 +370	+1,088%	+$19.1K	﹤0.01%	240
2023 Q2	$1.91K	Hold	34	–	–	﹤0.01%	622
2023 Q1	$1.54K	Hold	34	–	–	﹤0.01%	690
2022 Q4	$1.38K	Hold	34	–	–	﹤0.01%	800
2022 Q3	$2K	Buy	+34	New	+$2.46K	﹤0.01%	444
2022 Q1	$2K	Buy	35 +1	+3%	+$63	﹤0.01%	509
2021 Q4	$3K	Buy	+34	New	+$2.97K	﹤0.01%	451

Other funds holding CRSP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

SJS Investment Consulting's CRSP Position: Q2 2026 in Review

SJS Investment Consulting increased its CRISPR Therapeutics (CRSP) stake by 276% in Q2 2026, buying an estimated $4.96K and bringing the position to 128 shares worth $6.98K. The position accounts for ﹤0.01% of the portfolio, ranked #1242.

SJS Investment Consulting first reported a position in CRSP in Q4 2021 and has held it in 18 quarters since. The position peaked at $28.2K in Q1 2024. 252 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

SJS Investment Consulting held 128 shares of CRISPR Therapeutics worth $6.98K as of Q2 2026.
SJS Investment Consulting bought 94 CRISPR Therapeutics shares in Q2 2026, an estimated $4.96K.
CRISPR Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1242 holding.
SJS Investment Consulting first reported a position in CRISPR Therapeutics in Q4 2021 and has held it in 18 quarters since.
SJS Investment Consulting's CRISPR Therapeutics position peaked at $28.2K in Q1 2024.
252 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.